Media Newsroom of

Polaryx Therapeutics, Inc

140 E. Ridgewood Avenue, Suite 415, South Tower,
Paramus, NJ 07652

About Polaryx Therapeutics, Inc

Polaryx Therapeutics, Inc. is solely dedicated to developing drug candidates for late infantile neuronalceroid lipofuscinosis (LINCL) and other forms of NCL, for which there is currently no patient-friendlytreatment option available.

Recent Press Releases of Polaryx Therapeutics, Inc

Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of Krabbe Disease With PLX-300

Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of Krabbe Disease With PLX-300

Feb 11, 2021 - Polaryx Therapeutics, Inc (Press Release) - Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received both Rare Pediatric Disease and Orphan Drug Designations for the treatment of Krabbe Disease (a.k.a. Globoid Cell Leukodystrophy) with PLX-300 from the U.S. Food and…

Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of GM2 Gangliosidosis With PLX-300

Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of GM2 Gangliosidosis With PLX-300

Nov 25, 2020 - Polaryx Therapeutics, Inc (Press Release) - Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received from the U.S. Food and Drug Administration (FDA) both Rare Pediatric Disease and Orphan Drug designations for the treatment of GM2 gangliosidosis with PLX-300. GM2…

Polaryx Therapeutics Receives IND Approval From the FDA to Study PLX-200 Treatment for Patients With Juvenile Neuronal Ceroid Lipofuscinosis

Polaryx Therapeutics Receives IND Approval From the FDA to Study PLX-200 Treatment for Patients With Juvenile Neuronal Ceroid Lipofuscinosis

Apr 08, 2020 - Polaryx Therapeutics, Inc (Press Release) - Polaryx Therapeutics, a biotech company developing patient-friendly, small molecule therapeutics for lysosomal storage disorders, announced today that the Company has received an Investigational New Drug Application (IND) approval from the U.S. Food and Drug Administration (FDA) to study PLX-200 treatment…

Polaryx Therapeutics Submits Investigational New Drug Application to the U.S. FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis With PLX-200

Dec 23, 2019 - Polaryx Therapeutics, Inc (Press Release) - Polaryx Therapeutics Inc, a biotech company developing patient-friendly small molecule therapeutics for lysosomal storage disorders, such as Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and other forms of NCL, announced today that the Company has submitted an Investigational New Drug Application…

Polaryx Therapeutics Received Orphan Drug Designation From the European Medicines Agency (EMA) for the Treatment of Neuronal Ceroid Lipofuscinosis With PLX-200

Polaryx Therapeutics Received Orphan Drug Designation From the European Medicines Agency (EMA) for the Treatment of Neuronal Ceroid Lipofuscinosis With PLX-200

Feb 26, 2018 - Polaryx Therapeutics, Inc (Press Release) - Polaryx Therapeutics, Inc. is a biotech company developing patient-friendly oral small molecule therapeutics for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and other forms of NCL, commonly known as Batten disease. Neuronal Ceroid Lipofuscinosis qualifies as rare pediatric disease under Section…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login